Author: Aquestive Therapeutics, Inc.

Posted Date:

February 20, 2026

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

Aquestive Therapeutics, Inc.

February 20, 2026
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

Aquestive Therapeutics, Inc.

February 18, 2026
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Aquestive Therapeutics, Inc.

February 2, 2026